Infectious Disease Testing Market: Information by Product & Services (Kits & Reagents, Instruments), Technology (DNA Sequencing & NGS, PCR), End-User, and Region — Forecast till 2029

Apr 27, 2020   Infectious disease testing involves identifying the presence of foreign antigen/organism using testing tools and kits. Currently, most of the testing tools and kits available are for bacterial and viral infections. It is expected that the molecular techniques will replace most of these testing kits in the coming years. Advances in treating viral infections, active participation of the government, and rising demand for new research methods to monitor infectious diseases drive the market growth. ...
Request Free Sample Report

Report Description

Infectious disease testing involves identifying the presence of foreign antigen/organism using testing tools and kits. Currently, most of the testing tools and kits available are for bacterial and viral infections. It is expected that the molecular techniques will replace most of these testing kits in the coming years. Advances in treating viral infections, active participation of the government, and rising demand for new research methods to monitor infectious diseases drive the market growth.

Infectious-Disease-Testing-Market

HIV testing is the first critical step taken to address the HIV epidemic across the glove. In April 2019, the U.S. Preventive Service Task Force (USPSTF) announced a Broutine HIV screening. The emergence of fourth-generation HIV testing has enabled the identification of HIV infections in the acute phase or ‘window period’. The window period is the time between HIV infection and the detection of HIV antibodies leading to earlier diagnosis and engagement in all stages of care.

The infectious disease testing market was valued at USD 16.39 billion in 2019 and is expected to grow with a CAGR of 5.72% during the forecast period of 2020–2029.

Infectious-Disease-Testing-Market-Growth

Impact of COVID-19

COVID-19 has resulted in the introduction of several new testing methods with high accuracy at lower prices. On April 1, 2020, The Association of British HealthTech Industries (ABHI), BioIndustry Association (BIA), and the British In-Vitro Diagnostic Association (BIVDA) announced a global need for components of testing kits to ensure its supply in the healthcare sector. In South Korea, mass testing is conducted to identify the people affected by COVID-19. Moreover, laboratory tests provide better accuracy than testing kits. The manufacturers are channelizing efforts to develop advanced testing kits and adopting new strategies to reduce the cost and attain authorization from the government.

Infectious Disease Testing Market: Segmentation

Rising Prevalence of Infectious Diseases to Increase the Demand for Kits & Reagents

Based on products & services, the kits & reagents segment is projected to grow with the highest CAGR during the forecast period. The rising prevalence of infectious diseases is prompting the need for kits and reagents across the globe. Governments across the globe are actively working to address the dire situation. On March 09, 2020, Human Health Services (HHS) designed the first COVID-19 diagnostic system that can process up to 1,000 tests in 24 hours. The testing received active response from the U.S. Department of Health and Human Service’s Office of the Assistant Secretary for Preparedness and Response (ASPR). Similarly, Hologic, Inc. developed the first COVID-19 product test kit.

The Center for Disease Control and Prevention (CDC) developed a rapid test kit, CDC 2019 Novel Coronavirus (2019-nCov), Real-Time Real Transcriptase (RT-PCR), and Diagnostic Panel (CDC 2019-nCoV Real-Time RT-PCR) for the diagnosis of COVID-19. About 200 test kits were distributed across the U.S. domestic laboratories and international laboratories. The kit is specialized to test approximately 700 to 800 patient specimens.

DNA Sequencing and NGS Segment to Grow at a Significant Rate

By technology, the DNA sequencing and Next Generation Sequencing (NGS) segment is projected to grow at a significant rate in the infectious disease testing market. The rising application of NGS and advancements in sequencing technologies drive market growth. NGS has the potential to accelerate the early detection of disorders and the identification of pharmacogenetic markers to customize the treatment. Library preparation, assay designing, and data analysis are the key phases of entire NGS procedures. On September 12, 2018, the FDA launched the guidelines for NGS-based infectious disease diagnostics.

In the U.S., the New York State Department of Health uses whole-genome sequencing for viral infections such as influenza. Several companies are developing NGS based infectious disease tests in the country, which include Fry Labs, IDbyDNA, and Karius. The FDA is also actively working in the field of NGS, as it holds great potential to improve infectious disease diagnostics.

Hospitals/Clinical Laboratories Segment to Dominate the Market 

The hospital/clinical laboratories segment dominates the infectious disease testing market as they are easily accessible, offer quick test results, and provide flexibility in terms of scheduling specimen pickups. Rising population, increasing medicare reimbursement, and the emergence of advanced diagnostic tests drive the segment growth.

Regional Overview

North-America-Lead-Infectious-Disease-Testing-Market

Government Initiative to Drive North America’s Infectious Disease Testing Market

North America leads the infectious disease testing market as it possesses leading national clinical laboratories, highly developed healthcare systems, and easy accessibility to technologically advanced equipment. Currently, the clinical laboratories in the region are focussing on the next-generation sequencing technology as a novel development for infectious disease testing. The U.S. has been witnessing a lack of supply for testing kits due to coronavirus. Therefore, pathologists and clinical laboratories are actively working to develop new technologies for gene sequencing and diagnostic testing. The USFDA is also taking significant steps to develop efficient genetic disease diagnosis kits and has created a public database that contains information about genes, genetic variants, and relationship to infectious diseases.

Governments in North America are heavily investing in the development of robust healthcare infrastructure equipped with technologically advanced equipment, further driving the market growth. In the U.S. the government is continuously working to fight the COVID-19 pandemic and provide proper care to the patients. The Committee on Foreign Investments in the U.S. (CFIUS) is focusing on strengthening the country’s healthcare sector and providing assistance to increase the influx of foreign investments.

Key Players

  • Abbott Laboratories
  • Becton
  • Dickinson and Company
  • Biomérieux SA, Bio-Rad Laboratories
  • Danaher Corporation
  • Diasorin
  • Luminex
  • Meridian Bioscience
  • Quidel
  • Roche Diagnostics
  • Siemens AG
  • Thermo Fisher Scientific

Key Developments

  • On March 18, 2020, Abbott received emergency use authorization (EUA) from the Food and Drug Administration (FDA) for its molecular test for the identification of SARS-CoV-2, the virus that causes COVID-19. The company will deploy about 150,000 laboratory tests immediately.
  • On March 31, 2020, Becton Dickinson and Company (BD) announced the launch of a new Rapid Serology Test to detect exposure to COVID-19. The technique is a new point-of-care test that can detect antibodies in blood to confirm current or past exposure to COVID-19 in less than 15 minutes. The new test developed will be available through BD and distributed exclusively through Henry Schein, Inc. to healthcare providers throughout the U.S.

Infectious Disease Testing Market Segmentation

By Product & Services

  • Kits & reagents
  • Instruments
  • Software

By Technology

  • Immunodiagnostics
  • DNA sequencing & NGS
  • PCR

By End-User

  • Hospitals/clinical laboratories
  • Reference laboratories
  • Physician offices
  • Academic/research institutes

By Region

  • North America
  • Europe
  • Asia-Pacific
  • South America
  • The Middle East and Africa

Frequently Asked Questions (FAQs)

The infectious disease testing market was valued at USD 16.39 billion in 2019 and is expected to grow with a CAGR of 5.72% during the forecast period of 2020–2029.
Hospitals/Clinical Laboratories Segment is expected to be the leading segment in Infectious Disease Testing Market during the forecast period.
North America is expected to hold the highest market share in Infectious Disease Testing Market.
Advances in treating viral infections, active participation of the government, and rising demand for new research methods to monitor infectious diseases are the key factors expected to drive Infectious Disease Testing Market during the forecast period.
In 2019 Global Infectious Disease Testing Market was valued at USD 16.39 billion.
In 2020 Global Accessibility Testing Market was valued at USD 481 million.
Call us, email us, or chat with us! We encourage your questions and feedback. We have a research concierge team available at all times and included in every purchase.
We will send you an email with login credentials to access the report. You will also be able to download the pdf.
Basically choose Pay by Purchase Order when you are checking out. We will connect with you via email to set up your order.

Infectious disease testing involves identifying the presence of foreign antigen/organism using testing tools and kits. Currently, most of the testing tools and kits available are for bacterial and viral infections. It is expected that the molecular techniques will replace most of these testing kits in the coming years. Advances in treating viral infections, active participation of the government, and rising demand for new research methods to monitor infectious diseases drive the market growth.

Infectious-Disease-Testing-Market

HIV testing is the first critical step taken to address the HIV epidemic across the glove. In April 2019, the U.S. Preventive Service Task Force (USPSTF) announced a Broutine HIV screening. The emergence of fourth-generation HIV testing has enabled the identification of HIV infections in the acute phase or ‘window period’. The window period is the time between HIV infection and the detection of HIV antibodies leading to earlier diagnosis and engagement in all stages of care.

The infectious disease testing market was valued at USD 16.39 billion in 2019 and is expected to grow with a CAGR of 5.72% during the forecast period of 2020–2029.

Infectious-Disease-Testing-Market-Growth

Impact of COVID-19

COVID-19 has resulted in the introduction of several new testing methods with high accuracy at lower prices. On April 1, 2020, The Association of British HealthTech Industries (ABHI), BioIndustry Association (BIA), and the British In-Vitro Diagnostic Association (BIVDA) announced a global need for components of testing kits to ensure its supply in the healthcare sector. In South Korea, mass testing is conducted to identify the people affected by COVID-19. Moreover, laboratory tests provide better accuracy than testing kits. The manufacturers are channelizing efforts to develop advanced testing kits and adopting new strategies to reduce the cost and attain authorization from the government.

Infectious Disease Testing Market: Segmentation

Rising Prevalence of Infectious Diseases to Increase the Demand for Kits & Reagents

Based on products & services, the kits & reagents segment is projected to grow with the highest CAGR during the forecast period. The rising prevalence of infectious diseases is prompting the need for kits and reagents across the globe. Governments across the globe are actively working to address the dire situation. On March 09, 2020, Human Health Services (HHS) designed the first COVID-19 diagnostic system that can process up to 1,000 tests in 24 hours. The testing received active response from the U.S. Department of Health and Human Service’s Office of the Assistant Secretary for Preparedness and Response (ASPR). Similarly, Hologic, Inc. developed the first COVID-19 product test kit.

The Center for Disease Control and Prevention (CDC) developed a rapid test kit, CDC 2019 Novel Coronavirus (2019-nCov), Real-Time Real Transcriptase (RT-PCR), and Diagnostic Panel (CDC 2019-nCoV Real-Time RT-PCR) for the diagnosis of COVID-19. About 200 test kits were distributed across the U.S. domestic laboratories and international laboratories. The kit is specialized to test approximately 700 to 800 patient specimens.

DNA Sequencing and NGS Segment to Grow at a Significant Rate

By technology, the DNA sequencing and Next Generation Sequencing (NGS) segment is projected to grow at a significant rate in the infectious disease testing market. The rising application of NGS and advancements in sequencing technologies drive market growth. NGS has the potential to accelerate the early detection of disorders and the identification of pharmacogenetic markers to customize the treatment. Library preparation, assay designing, and data analysis are the key phases of entire NGS procedures. On September 12, 2018, the FDA launched the guidelines for NGS-based infectious disease diagnostics.

In the U.S., the New York State Department of Health uses whole-genome sequencing for viral infections such as influenza. Several companies are developing NGS based infectious disease tests in the country, which include Fry Labs, IDbyDNA, and Karius. The FDA is also actively working in the field of NGS, as it holds great potential to improve infectious disease diagnostics.

Hospitals/Clinical Laboratories Segment to Dominate the Market 

The hospital/clinical laboratories segment dominates the infectious disease testing market as they are easily accessible, offer quick test results, and provide flexibility in terms of scheduling specimen pickups. Rising population, increasing medicare reimbursement, and the emergence of advanced diagnostic tests drive the segment growth.

Regional Overview

North-America-Lead-Infectious-Disease-Testing-Market

Government Initiative to Drive North America’s Infectious Disease Testing Market

North America leads the infectious disease testing market as it possesses leading national clinical laboratories, highly developed healthcare systems, and easy accessibility to technologically advanced equipment. Currently, the clinical laboratories in the region are focussing on the next-generation sequencing technology as a novel development for infectious disease testing. The U.S. has been witnessing a lack of supply for testing kits due to coronavirus. Therefore, pathologists and clinical laboratories are actively working to develop new technologies for gene sequencing and diagnostic testing. The USFDA is also taking significant steps to develop efficient genetic disease diagnosis kits and has created a public database that contains information about genes, genetic variants, and relationship to infectious diseases.

Governments in North America are heavily investing in the development of robust healthcare infrastructure equipped with technologically advanced equipment, further driving the market growth. In the U.S. the government is continuously working to fight the COVID-19 pandemic and provide proper care to the patients. The Committee on Foreign Investments in the U.S. (CFIUS) is focusing on strengthening the country’s healthcare sector and providing assistance to increase the influx of foreign investments.

Key Players

  • Abbott Laboratories
  • Becton
  • Dickinson and Company
  • Biomérieux SA, Bio-Rad Laboratories
  • Danaher Corporation
  • Diasorin
  • Luminex
  • Meridian Bioscience
  • Quidel
  • Roche Diagnostics
  • Siemens AG
  • Thermo Fisher Scientific

Key Developments

  • On March 18, 2020, Abbott received emergency use authorization (EUA) from the Food and Drug Administration (FDA) for its molecular test for the identification of SARS-CoV-2, the virus that causes COVID-19. The company will deploy about 150,000 laboratory tests immediately.
  • On March 31, 2020, Becton Dickinson and Company (BD) announced the launch of a new Rapid Serology Test to detect exposure to COVID-19. The technique is a new point-of-care test that can detect antibodies in blood to confirm current or past exposure to COVID-19 in less than 15 minutes. The new test developed will be available through BD and distributed exclusively through Henry Schein, Inc. to healthcare providers throughout the U.S.

Infectious Disease Testing Market Segmentation

By Product & Services

  • Kits & reagents
  • Instruments
  • Software

By Technology

  • Immunodiagnostics
  • DNA sequencing & NGS
  • PCR

By End-User

  • Hospitals/clinical laboratories
  • Reference laboratories
  • Physician offices
  • Academic/research institutes

By Region

  • North America
  • Europe
  • Asia-Pacific
  • South America
  • The Middle East and Africa

Frequently Asked Questions (FAQs)

The infectious disease testing market was valued at USD 16.39 billion in 2019 and is expected to grow with a CAGR of 5.72% during the forecast period of 2020–2029.
Hospitals/Clinical Laboratories Segment is expected to be the leading segment in Infectious Disease Testing Market during the forecast period.
North America is expected to hold the highest market share in Infectious Disease Testing Market.
Advances in treating viral infections, active participation of the government, and rising demand for new research methods to monitor infectious diseases are the key factors expected to drive Infectious Disease Testing Market during the forecast period.
In 2019 Global Infectious Disease Testing Market was valued at USD 16.39 billion.
In 2020 Global Accessibility Testing Market was valued at USD 481 million.
Call us, email us, or chat with us! We encourage your questions and feedback. We have a research concierge team available at all times and included in every purchase.
We will send you an email with login credentials to access the report. You will also be able to download the pdf.
Basically choose Pay by Purchase Order when you are checking out. We will connect with you via email to set up your order.